This study aims to enroll a robust cohort of NAFLD patients who undergo Intragastric Balloon placement through a multidisciplinary program approach to evaluate clinical and patient-reported outcomes for at least one-year post-placement.

Inclusion Criteria:

• Obese (defined as a BMI >30 kg/m2 )
• Men and women scheduled to undergo immunoglobulin B placement at Methodist Dallas Medical Center(MDMC)
• 18 years or older in age
• Able to read and understand the study information
• Personally signed and dated informed consent form indicating that the subject has been informed of all pertinent aspects of the study
• Subject is willing and able to comply with the scheduled visits, questionnaires, treatment plan, and other study procedures

Exclusion Criteria:

• Not meeting inclusion criteria
• Pregnant women

This single-center, prospective cohort study will investigate NAFLD patients enrolled in a multidisciplinary immunoglobulin B placement program seen at Methodist Dallas Medical Center (MDMC) beginning January 2023 through December 2026.